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involving people with bipolar and schizophrenia in
a community-based setting (PARTNERS2): study
protocol for the development of two core outcome
sets
Thomas Keeley1*, Humera Khan1, Vanessa Pinfold2, Paula Williamson3, Jonathan Mathers1, Linda Davies4,
Ruth Sayers2, Elizabeth England1, Siobhan Reilly5, Richard Byng6, Linda Gask7, Mike Clark8, Peter Huxley9,
Peter Lewis10, Maximillian Birchwood11 and Melanie Calvert1Abstract
Background: In the general population the prevalence of bipolar and schizophrenia is 0.24% and 1.4% respectively. People
with schizophrenia and bipolar disorder have a significantly reduced life expectancy, increased rates of unemployment and
a fear of stigma leading to reduced self-confidence. A core outcome set is a standardised collection of items that should be
reported in all controlled trials within a research area. There are currently no core outcome sets available for use in
effectiveness trials involving bipolar or schizophrenia service users managed in a community setting.
Methods: A three-step approach is to be used to concurrently develop two core outcome sets, one for bipolar and one
for schizophrenia. First, a comprehensive list of outcomes will be compiled through qualitative research and systematic
searching of trial databases. Focus groups and one-to-one interviews will be completed with service users, carers and
healthcare professionals. Second, a Delphi study will be used to reduce the lists to a core set. The three-round Delphi
study will ask service users to score the outcome list for relevance. In round two stakeholders will only see the results of
their group, while in round three stakeholders will see the results of all stakeholder group by stakeholder group. Third, a
consensus meeting with stakeholders will be used to confirm outcomes to be included in the core set. Following
the development of the core set a systematic literature review of existing measures will allow recommendations
for how the core outcomes should be measured and a stated preference survey will explore the strength of people’s
preferences and estimate weights for the outcomes that comprise the core set.
Discussion: A core outcome set represents the minimum measurement requirement for a research area. We aim to
develop core outcome sets for use in research involving service users with schizophrenia or bipolar managed in a
community setting. This will inform the wider PARTNERS2 study aims and objectives of developing an innovative
primary care-based model of collaborative care for people with a diagnosis of bipolar or schizophrenia.* Correspondence: T.J.H.Keeley@bham.ac.uk
1School of Health and Population Sciences, University of Birmingham,
Birmingham B15 2TT, UK
Full list of author information is available at the end of the article
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Mental illness is the single largest cause of disability in
the UK, contributing to 22.8% of the total burden of dis-
ease [1]. An evaluation of primary care service provision
for severe mental illness (SMI) indicates that 94% of ser-
vice users had a recorded diagnosis of schizophrenia or
bipolar disorder [2]. In the general population the preva-
lence of schizophrenia is up to 1.4% and for bipolar I
disorder it is 0.24% [3]. People with schizophrenia and
bipolar disorder have a significantly reduced life expect-
ancy, increased rates of unemployment and experience
of stigma leading to reduced self-confidence and self-
esteem [4,5]. The service cost alone of treating these dis-
eases is estimated at £3.8 billion and expected to rise to
£6.3 billion per year [6,7].
Randomised controlled trials (RCTs) can provide ro-
bust evidence to inform mental health and social care.
Outcomes assessed in trials can help inform decisions
regarding both individual care and policy formation at
local, regional or national levels. To do this outcomes
need to be relevant and of value to stakeholders, such as
the services users, family, carers, health and social care
professionals and decision makers.
The use of numerous trial outcomes within the same
research area can cause challenges. The most accessed
and cited Cochrane reviews of 2009 all reported prob-
lems with heterogeneity of outcomes [8,9]. Within men-
tal health research, trials frequently use a broad range of
outcome measures. A recent survey of 10,000 RCTs in
schizophrenia reported that 2,194 different measure-
ments were used, with a new outcome being reported
every fifth trial [10]. This has the potential to reduce the
ability to synthesise results. Furthermore, many of the
measures used in these trials have been selected by re-
searchers and clinicians and may not reflect outcomesa
that are relevant to all stakeholders.
The use of numerous outcome measures within a con-
trolled trial can also result in reporting bias. RCTs
should specify a priori the primary and secondary out-
come measures to be used to test a study hypothesis
[11-13]. However, reporting bias occurs when the au-
thors report a subsection of the outcome measures,
based on the significance of the findings [14]. Reporting
bias has been shown to be a widespread phenomenon in
medical literature generally [15,16], as well as in mental
health specifically [17].
These issues can be addressed through the use of a
core outcome set with input from a range of stake-
holders including service users with lived experience of
SMI and carers. A core outcome set is a standardised
collection of items that should be reported in all con-
trolled trials within a research area [9]. It represents the
minimum outcomes that should be measured and re-
ported [18]. Trialists are not restricted to these measuresand can use additional measures to those in the core set.
However, the core set marks the basic requirement of
what outcomes need to be measured and reported.
Core outcome sets for effectiveness trials involving
service users with bipolar or schizophrenia, managed
in a community setting, have the potential to reduce
reporting bias and facilitate evidence synthesis. The as-
sessment of similarities in outcomes between the two
sets may allow the identification of common outcomes
for use in SMI trials including both groups. Community
setting refers to care or support received while living in
the community (i.e. not in hospital as an in-patient). A
search of the COMET database showed no core outcome
sets are currently available for use in controlled trials
recruiting adult participants with bipolar or schizophrenia,
managed in a community setting.
The PARTNERS2 study has been funded through the
NIHR under its Programme Grants for Applied Research
programme (grant reference no. RP-PG-0611-20004). It
aims to help primary care and community-based mental
health services work more closely and efficiently to-
gether through developing and trialling an innovative
primary care-based model of collaborative care for
people with a diagnosis of bipolar and schizophrenia.
Work commenced in March 2014 and is scheduled for
completion in 2019.
Aims and objectives
Aims
The aim of this study is to develop two individual core
outcome sets for schizophrenia and bipolar for use in SMI
trials involving adult service users recruited from a commu-
nity setting. In addition, we will compare the two core out-
come sets and identify common outcomes to be assessed in
SMI trials including both groups (see Figure 1).
Objectives
The specific objectives are threefold. First, to identify a
comprehensive list of outcomes that are relevant for trials
involving schizophrenia and bipolar disorder in a commu-
nity setting, to develop two core outcome sets based on
this comprehensive list and, where possible, to identify
common outcomes across core outcome sets. The second
is to identify potential reliable, valid and responsive mea-
sures that could be used to assess the outcomes included
in the core sets. A further objective is to estimate the
strength of people’s preferences and weights for key out-
comes/items included in the patient-reported outcome
measures (PROMs) that comprise the core sets.
Methods
Overview
A three-step approach to concurrently developing each
of the core outcome sets will be used [9,19]. First, a
Figure 1 Identification of a core outcome sets for schizophrenia and bipolar.
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holders will be compiled through qualitative research
and through a review of outcomes reported in existing
trials. Focus groups and one-to-one interviews with key
stakeholders will be used. Second, the comprehensive
list will be reduced to a core outcome set through Del-
phi methodology. Third, a consensus meeting with
stakeholders will confirm the outcomes to be included
in the core sets.
Two additional steps will then be completed. A system-
atic literature review of existing measures and a stake-
holder discussion will allow recommendations as to how
the core outcomes should be measured. Finally, a stated
preference survey will explore the strength of people’s
preferences and estimate weights for key outcomes/items
included in the PROMs that comprise the core sets.
Ethical approval for the study has been sought and
granted from the National Research Ethics Service (NRES)
West Midlands – Edgbaston (reference no. 14/WM/0052).
Step 1: Qualitative research
The opinions of key stakeholders will be sought using
focus groups and one-to-one interviews. The qualitative
methods will differ between stakeholder groups due to
methodological and practical considerations, such as
time pressures of healthcare professionals.
Focus groups and one-to-one interviews with service users
and carers
Participants People with schizophrenia or bipolar who
use community services to support their health andwell-being and their family members and carers will be
purposively sampled by age, gender, condition and geo-
graphical location. To be eligible for inclusion in a focus
group or interview service users must: self-identify as
having a lifetime or current clinical diagnosis of schizo-
phrenia or bipolar; be receiving treatment in a commu-
nity setting; be over 18 and under 65 years old and
speak English. Carers must be a self-reported carer of a
person who meets the service user criteria and speaks
English.
Recruitment Recruitment will occur through NHS Trust
clinics and via the third sector organisations, such as
MIND, National Survivor User Network (NSUN), Rethink
Mental Illness, Bipolar UK and Carers in Partnership. Ini-
tial contact will be via email, post and leaflets and posters
displayed in NHS clinics and third sector organisations.
Interested participants will be advised to contact the study
team by post, email or phone. The study team will check
the eligibility and identify potential dates for participation.
At this point the research will be described in greater de-
tail and potential participants will be given the opportunity
to ask questions. An invitation letter and an information
sheet will be sent to eligible participants that wish to par-
ticipate. A reminder phone call will be scheduled, or letter
will be sent, in the week prior to the focus group. For
those participants preferring to take part in one-to-one
interviews, these will be arranged and a reminder phone
call scheduled. For both focus groups and one-to-one
interviews informed consent will be taken prior to start-
ing data collection.
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cruited to the study is dependent on a number of fac-
tors: the proportion of the data gathered through focus
groups as opposed to one-to-one interviewsb, the size of
the focus groups that are held and the point at which
data saturation is achieved. It is anticipated that roughly
24 service users (12 with each diagnosis) and up to 10
carers will be recruited to the qualitative stage of the
work.Methodology Focus groups and one-to-one interviews
will seek to identify clinical, social and psychological
outcomes that are important to service users and carers.
Participants will be encouraged to discuss the impact
that their illness has upon them and their life. They will
be asked to explain how treatment or management of
their illness affects them. Participants will be encouraged
to explore the important short- and long-term impacts
of treatment. A topic guide, developed in collaboration
with a researcher with lived experience of serious mental
illness, will be used as an aide memoire and to add
structure to the discussion.
Focus groups will be split by clinical diagnosis resulting
in groups of bipolar service users, bipolar carers, schizo-
phrenia service users and schizophrenia carers. This will
allow identification of outcomes relevant to bipolar and
schizophrenia service users and any common outcomes
across diagnoses.
The consent process will be completed on the day of
the focus group or interview, before starting the dis-
cussion, in order to allow assessment of capacity to
participate on that day. Prior to the consent form being
signed, participants will be asked if they have read and
understood the information provided to them and will
have the opportunity to ask any further questions. The
audio recording of discussions, the anonymity process
and the ability of the participant to withdraw from the
focus group at any point will be verbally emphasised at
the start.One-to-one interviews with commissioners, policy makers
and health and social professionals
Participants Consultant psychiatrists, mental health
leads within clinical commissioning groups, general
practitioners with a special interest in or professional ex-
perience (either clinical or commissioning) of serious
mental illness, social workers, community psychiatric
nurses, commissioners, policy makers and those with
relevant roles in third sector organisationsc will be in-
cluded as participants. Sampling will be stratified and
purposive so as to ensure suitable variation of profes-
sional groups is achieved.Recruitment Health and social care professionals will be
recruited primarily from West-Midlands and Lancashire.
Publically available lists and professional contacts of
project investigators will be used to identify potential
participants.
Potential participants will be contacted via an email,
containing a study information sheet, requesting their
participation in the study. A reminder email will be sent
2 weeks after the original email. Upon a positive reply
from a potential participant a date will be set for a tele-
phone interview. A consent form will be sent to partici-
pants via email upon agreeing to participate. Verbal
consent will be taken and recorded at the start of the
interview and a request will be made for the participant
to return a signed copy of the consent form via post.
The number of health and social care professionals re-
cruited to the study is dependent on adequately sam-
pling each of the professional groups named above and
the point at which data saturation is reached. It is antici-
pated that roughly 20 participants will be recruited to
the qualitative stage of the work.One-to-one interview methodology A semi-structured
interview will be undertaken. A topic guide will be used
to direct the conversation; however the semi-structured
nature of the discussion will allow emergent themes or
pertinent points to be explored. Participants will be
asked to discuss how bipolar and schizophrenia affects a
person’s life, how care and support can improve out-
comes that are important to the patient and what out-
comes should be assessed in research with these
populations. One half of the interview will be given to
discussing bipolar and the other half to schizophrenia.
The sequence in which the conditions are discussed will
be varied. Where a participant has particular expertise in
one condition the whole of the interview will be devoted
to discussing that condition (this is expected in a minor-
ity of cases).Qualitative data analysis
Focus groups and one-to-one interviews will be digitally
audio-recorded and transcribed verbatim. Transcripts
will be coded using the computer-assisted qualitative
data analysis software, such as Dedoose or Nvivo. The
first version of the coding structure will be formed dur-
ing the analysis of the early data and therefore grounded
in the data. For the service user and carer data two re-
searchers (one with and one without lived experience)
will concurrently analyse all data. For the health and so-
cial care professional data the facilitator of the interviews
will lead the analysis of data, with 20% checked for ac-
curacy and completion by a researcher with lived experi-
ence of mental illness.
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lysis of the transcripts will be completed [20,21]. The it-
erative nature of the analysis will allow themes identified
in the early focus groups to be explored in greater
depths with later groups. The analysis will focus on
forming a comprehensive list of outcomes that are im-
portant to stakeholders. The structure and length of this
list will be dependent on the data.
During the qualitative analysis outcomes identified as
relevant to schizophrenia and bipolar service users will
be identified separately. Evidence of notable conver-
gence in the outcomes in the two groups may indicate
that in addition to the bipolar and schizophrenia core
outcome sets, the potential for a joint core outcome set
could be considered. Considerable difference in the
outcomes at this stage would suggest that this is not a
workable possibility.Review of literature
A focussed review of literature and databases will be
completed concurrently with the qualitative work in
order to ensure a complete set of relevant outcomes is
identified. Through this approach the potential of not
including outcomes that are important to stakeholders
is reduced. The findings of the review will be cross-
referenced with the results of the qualitative work to
ensure completion.
The literature and databases reviewed will be: Cochrane
registers, a recent Cochrane review [22], ongoing trials
adopted by the CRNs and trial registries, the outcomes
compendium [23] and Outcome Measurement in Mental
Health: the views of service users [24]. The following data
will be extracted from the literature: basic trial informa-
tion, investigator names, year of study, study setting, pri-
mary outcome, secondary outcomes and measures used.
The results of the qualitative work and the literature
review will be merged to form two separate comprehen-
sive lists of outcomes for bipolar and schizophrenia.
These will be finalised through discussion with repre-
sentatives of stakeholder groups, including our Lived
Experience Advisory Panel (LEAP). The LEAP will con-
sist of people with personal experience of living with
schizophrenia or bipolar (as service users or carers) will
be recruited to form Lived Experience Advisory Panels,
combining their expertise from lived experience with
their insights into research design and delivery. These
LEAPs will meet regularly to promote the study locally,
problem-solve and ground interpretation. LEAPs will
support the development of the core outcome set,
through reviewing findings from the qualitative data,
helping to synthesise the information and informing the
development of a Delphi study that is accessible and en-
gaging for service user and carer participants, The listwill be reviewed by the steering committee and phrased
to ensure common understanding.Step 2: Delphi Study and stakeholder consensus meeting
An online Delphi study will be used to reduce the lists
of potential outcomes to two smaller core sets. A Delphi
study is a sequential process through which the opinions
of participants are sought anonymously [25]. Participants
in a Delphi study do not interact directly; rather after
the completion of each round of questionnaires, the col-
lated group response is fed back to participants. In this
way equal weight is given to all those who participate
and the potential of an individual or group of individuals
being overly influential or dominant in the process is
controlled for [26].
A group of participants, representing the key stake-
holder groups of service users, carers and health and so-
cial care professionals, will be recruited to the study.
Those participating in the qualitative research will be in-
vited to participate in the Delphi study. There is no con-
sensus on the optimal sample size for a Delphi study;
therefore recruitment is based on previous Delphi stud-
ies [27] and will likely result in between 75 and 100 par-
ticipants being recruited to the first round of the Delphi.
Participants will be purposively sampled to ensure repre-
sentation of all stakeholder groups; exact numbers will
be informed by previous research [27] and will be agreed
upon in discussion with the steering committee and
LEAP. The requirement for participants to complete all
rounds of the Delphi study will be emphasised during
the process of recruitment. To limit attrition appropriate
procedures will be followed [27], including reminder
emails.
Potential participants will be recruited from NHS
trusts as well as through third sector organisations, in-
cluding MIND, Bipolar UK, the McPin Foundation and
NSUN. Healthcare professionals and individuals in-
volved in research will be approached via an invitation
email. Service users and carers will be recruited via
email, post and leaflets and posters in NHS clinics and
third sector organisations.Delphi round one
In the first round participants will be asked to register
online. The registration process will capture participants’
name, email addresses and additional participant infor-
mation. Service users will be asked for their clinical diag-
nosis and the current state of health; carers will be asked
for the same information of the person for which they
care; healthcare professionals and commissioners will be
asked for their professional role, seniority and clinical
specialism. A unique identifier will be assigned to each par-
ticipant to allow identification of individuals completing
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available upon request.
The list of outcomes identified through the qualitative
research and review will be presented to participants.
Participants will be asked to rate the importance of each
of the outcomes on a nine-point Likert scale, one being
not important and nine being critical. Through the use
of a free text box participants will be able to provide
feedback on their choices if they wish. Through inclu-
sion of the following question participants will be able to
propose additional outcomes that were not identified in
the qualitative work: ‘Can you think of any additional out-
comes that should be measured in research trials with bi-
polar/schizophrenia service users?’ A free text box will be
available for participants to list additional outcomes.
Round one analysis
The response rate will be assessed at the end of round
one. The total number of respondents completing the
round will be assessed by stakeholder groups (service
users, carers and healthcare professionals). The total
number of respondents will be compared to the number
of respondent who agreed to participate (to analyse attri-
tion between recruitment and survey) and the number
who registered at the start of the survey (to analyse
within survey attrition).
If low numbers of responders are observed in one or
more of the stakeholder groups the methodology of the
Delphi study will be re-assessed. Potential changes in-
clude the re-opening of round one recruitment or an
additional reminder message to non-responders. If low
numbers are observed in one stakeholder group only,
the potential of merging groups will be assessed and dis-
cussed with the LEAP and study management team.
Such decisions will be made prior to viewing results
from round one to minimise bias. The following proto-
col is based on the assumption of adequate respondent
numbers.
Data from round one will be analysed by stakeholder
group. For each outcome, the number of respondents
and distribution of scores will be summarised and ana-
lysed. Any additional information in a free text field will
be considered by members of the study team and the
LEAP to ensure they represent new outcomes not iden-
tified in previous qualitative work. If it is the case that
they do represent a new outcome not already identified
they will be included in round two.
Delphi round two
Participants from round one will be invited to partici-
pate in round two. All outcomes from round one will be
carried forward into round two. The results of round
one will be available for the participants in round two to
review. Participants will only be able to view the resultsof their stakeholder group. For example, service users
will be able to view the results of the service user group,
but not the health and social care professional group.
The number of respondents and distribution of respond-
ent scores by clinical diagnosis will be presented.
After viewing the results of their stakeholder group
from round one, participants will be asked to again rate
the importance of each of the outcomes on a nine-point
Likert scale. Participants will have the opportunity to re-
view and change their scores from the previous round.Delphi round two analysis
Data for round two will again be analysed by stakeholder
group. For each outcome in round two, the proportion
of participants scoring 1–3, 4–6 and 7–9 on the nine-
point Likert scale will be calculated for each item. All
outcomes will be carried forward to the next round.Delphi round three
In round three participants will be presented with results
of all stakeholder groups, by stakeholder group. All par-
ticipants will see the scores from each stakeholder
group. The proportion of participants scoring 1–3, 4–6
and 7–9 for each outcome will be presented. Participants
will again be asked to use the nine-point scale to indi-
cate whether they think the outcome should be included
in the core outcome set.Delphi round three analysis
Data for round three will be analysed by both the stake-
holder group and all participants. For each outcome the
distribution of scores will be summarised. Each outcome
will be classified as “consensus in”, “consensus out” and
“no consensus” using the following classification: “Con-
sensus in”, consensus that the outcome should be in-
cluded in a core outcome set, will be defined as greater
than 70% of participants scoring 7–9 and less than 25%
of participants scoring 1–3. “Consensus out”, consensus
that the outcome should not be included in a core out-
come set, will be defined as greater than 70% of partici-
pants scoring 1–3 and less than 15% scoring 7–9. “No
consensus” will be said to have occurred when any other
distribution of scores occurs. Such classifications are
somewhat arbitrary and subjective, however stipulating
the ex-ante controls for bias and prior beliefs informing
the analysis post-hoc. Where “no consensus” has oc-
curred the outcome will undergo further analysis, in-
cluding assessment of the mean score in the final round.
The analysis will be summarised by stakeholder group
and all participants and comparison will be drawn be-
tween groups. This analysis, for both bipolar and schizo-
phrenia, will be presented to the consensus meeting.
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On completion of the Delphi Study a face-to-face con-
sensus meeting will be held with key stakeholders, in-
cluding some members of the LEAP. The results of each
round of the Delphi study will be presented to the meet-
ing, with the consensus results from the round three
analyses used as the starting point for discussion. The
final format of the meeting will be decided upon at the
end of the Delphi exercise and after reviewing the ex-
perience of core outcome set projects currently in pro-
gress and drawing upon advice of COMET members.
The purpose of the meeting is to ratify the final out-
come set; therefore the agenda of the meeting and pro-
cesses used will be in part dependent on the consensus
achieved through the Delphi study. The meeting will
focus on resolving situations where “no consensus”
was found to have occurred and where two outcomes
classified as “consensus in” appear to assess a similar
construct.
Step 4: Systematic review of outcome measures and
stakeholder meeting
The Delphi process and subsequent consensus meeting
identify what core outcomes should be measured for
studies involving schizophrenia and bipolar service users
recruited from a community setting. A systematic review
of the literature will be completed to assess the proper-
ties of existing measures used in research with bipolar
and schizophrenia. Measures identified will be matched
with the outcomes from the Delphi study for consider-
ation in a later stakeholder meeting.
A systematic or rapid review [28,29] will be used to
identify potential measures for inclusion in the core out-
come set. This review will identify papers reporting re-
search with people with bipolar or schizophrenia being
treated in a community setting. Interventional and obser-
vational primary research will be included in the review.
Measurement tools used in the identified studies will be
collated and “matched” with the outcomes identified
through the qualitative work and the Delphi process [30].
The measurement and psychometric properties of the
measures identified will be assessed using the COSMIN
checklist [31,32]. Specifically measures will be assessed for
published evidence of construct validity [33], reliability
[34] and responsiveness [35]. Measures that have accept-
able psychometric property portfolios will be presented to
the LEAP in order to assess the face validity [36] of these
measures in this population.
The results of the review, assessment of the psycho-
metric portfolios of the measures and LEAP group as-
sessments of the measures will be presented at a
stakeholder meeting. This meeting will seek consensus
on recommendations of how to measure the outcomes
and which measurement tools are most appropriate foruse. The agenda of the meeting, and the process through
which recommendations will be formed, will be designed
based on the number of outcomes identified in the Delphi
study and the number of corresponding measures identi-
fied in the review.
Step 5: Stated preference survey
The key patient outcomes to be compared and explored
in the stated preference survey will be defined from the
evidence identified in steps 1–4 above. It may be that
the work in stages 1–4 identifies one outcome and asso-
ciated outcome measure that is considered the primary
outcome for both people with schizophrenia and/or bi-
polar disorder. In this case, the stated preference survey
will be designed to estimate the preferences of service
users, carers and relevant healthcare professionals and
policy makers for key domains of that outcome measure.
However, there may be a number of outcomes that are
identified as important. In this case the stated preference
attributes and levels will be developed from the results
of stage 1–4 and refined by discussions with the LEAP
and study team. LEAP participants will also be asked to
participate in a pilot of the survey measure.
Service users, carers and relevant health and social
care professionals and commissioners will be asked to
complete the stated preference survey to identify their
preferences and priorities for the different types of out-
comes identified as important to measure in the core set.
The participants will be drawn from the focus groups and
Delphi panels.
The stated preference survey will use orthogonal main
effects. Responses from the questionnaires will be ana-
lysed using appropriate logistic or probit regression ana-
lyses. The coefficients for each attribute will indicate the
direction of preference for that attribute. Marginal rates
of substitution will be calculated to estimate the relative
utility of the attribute. These analyses will be used to:
(1) explore the relative importance and preference for
different aspects of outcome included in the core set
(or primary outcome) and
(2) estimate preference weights that can be used to
combine key domains into a single index.
Discussion/conclusion
A core outcome set represents the minimum measure-
ment requirement for a research area. Studies within that
area which are focussed on a sub-set of service users, for
example rapid cycling bipolar, or focussed on specific area,
for example collaborative care, may feel the requirement
to supplement the a core outcome set with additional,
relevant measures assessing different outcomes.
This protocol has a number of strengths, including the
commitment to ensuring service users and carers are
Keeley et al. Trials  (2015) 16:47 Page 8 of 9represented, using qualitative work to identify outcomes
that may not currently be used in research and following
best practice developed through the COMET initiative.
Some potential limitations of this work should be
highlighted. The requirement of service users and carers
to self-identify could induce bias or inaccuracy. The use of
an online Delphi survey will limit participation to those
who are computer literate and the qualitative work cannot
include those who do not have a conversational level of
spoken English. Reasonable steps will be taken to minim-
ise the impact of these limitations upon the work and they
will be reflected upon when presenting findings.
There are no core outcome sets for use in research in-
volving service users with schizophrenia or bipolar man-
aged in a community setting. The PARTNERS2 project
aims to develop core outcome sets for these research
areas by drawing on outcomes identified as important by
relevant stakeholders and using the expertise of our
LEAP. Given that 94% of diagnoses for SMI in primary
care were for bipolar or schizophrenia we anticipate that
it is likely that there will be some degree of convergence
between the two sets developed [2]. The potential of de-
veloping one core outcome set for use in SMI research
in a community setting will be continually assessed
throughout this work. It is anticipated that successful
completion of this work will improve the ability of future
research to draw comparison between studies involving
people with schizophrenia and bipolar and improve in-
terpretation of results. The challenges of developing a
COS in this area and with this population will be dis-
cussed and subsequent weaknesses of the research will
be highlighted.Trial status
At the time of manuscript submission the status of the
trial is ongoing. Patient recruitment has not been
completed.Endnotes
aWhere the term outcome or outcomes is used this re-
fers to an outcome domain (for example, quality of life
or physical functioning). The term outcome measure will
be used to refer to measurement tools.
bParticipants will be encouraged to take part in focus
groups; however some participants may feel unable to
participate in such groups. Reasons could be practical
(e.g. they cannot attend on the date of the focus group)
or more complex (e.g. the format of a focus group is in-
timidating for the participant). In these situations the
potential participant will be offered the opportunity to
take part in a one-to-one interview.
cThese participants will be referred to as “health and so-
cial care professionals” in the remainder of this protocol.Abbreviations
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